Cargando…
TRLS-08. CNS PENETRATION AND PRELIMINARY EFFICACY OF SACUTIZUMAB GOVITECAN IN BREAST BRAIN METASTASIS AND GLIOBLASTOMA: A SURGICAL STUDY
Sacituzumab govitecan (SG) is an antibody drug conjugate (ADC) that targets Trop-2 for the selective delivery of SN-38 to tumors. SG carries SN-38, a topoisomerase inhibitor active in the nanomolar range for most cells (including TNBC and GBM) and freely cross the blood brain barrier. SN-38 is conju...
Autores principales: | Brenner, Andrew, Floyd, John, Surapaneni, Prathiba, Madhusudanan-Kunnuparampil, Vinu, Tiziani, Stefano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213261/ http://dx.doi.org/10.1093/noajnl/vdz014.041 |
Ejemplares similares
-
TRLS-08. EXPERIENCE WITH THE SELECTIVE FIBROBLAST GROWTH FACTOR INHIBITOR ERDAFITINIB IN THREE PEDIATRIC PATIENTS WITH CNS TUMORS
por: Stepien, Natalia, et al.
Publicado: (2023) -
TRLS-15. TARGETED THERAPY IN PEDIATRIC CNS TUMORS - A SINGLE INSTITUTION EXPERIENCE
por: Olsen, Braden, et al.
Publicado: (2023) -
TRLS-01. FDA ANALYSIS OF EXPANDED ACCESS USE IN PEDIATRIC PATIENTS WITH CNS TUMORS FROM 2015 TO 2020
por: Duke, Elizabeth, et al.
Publicado: (2023) -
Sacituzumab Govitecan: First Approval
por: Syed, Yahiya Y.
Publicado: (2020) -
Sacituzumab govitecan for breast cancer
Publicado: (2022)